Salivary Gland Cancer

Detailed, systematic histopathological and immunohistochemical (IHC) assessment for validation and confirmatory diagnosis is imperative. An added evaluation for tumour outcome with affirmative markers (DOG1), proliferative markers (Ki67), add value in diagnosis and prognostication of this tumour.

Surgical resection is the main treatment, and diagnosis requires confirmation through histopathology, immunohistochemistry, and special staining. CRTC1-MAML2 fusion can also assist in diagnosis.

BCA is a very rare tumor of the lacrimal gland, but complete resection is the effective treatment. Postoperative follow-up is necessary due to the possibility of malignant transformation.

Recognition of LG-TNBCs is essential to prevent overtreatment and guide personalized patient management. Molecular characterization provides diagnostic confirmation and therapeutic opportunities, particularly for NTRK-fusion-positive tumors treatable with targeted inhibitors, highlighting the importance of precision medicine in rare breast tumors.

P2, N=88, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting

Fluorescence in situ hybridization revealed MAML2 rearrangement with RNASeq confirming a YAP1::MAML2 fusion product. This case highlights a novel salivary gland malignancy type arising from lymphadenoma, for which molecular testing was critical in establishing primary origin, and thus excluding the more common metastatic squamous cell carcinoma.

There are high demands placed on pathologists for accurate intraoperative frozen section diagnoses, which can be challenging. This summary of two NSL cases and a literature review may aid in the clinical recognition of NSL and improve the accurate diagnosis of this benign tumor.

This study demonstrated that PSMA is commonly expressed in malignant SGTs, suggesting that PSMA could be effective for targeted imaging and therapeutics in these tumor types.

This case highlights the importance of extended molecular testing when EWSR1 FISH is negative; as alternate FET::ETS fusions may underlie the diagnosis.

However, the classification of the neoplasm remains a controversial issue, with the WHO noting that it is still not established whether SG IPMN should be classified separately or within the mucinous adenocarcinoma spectrum as a potential precursor [2]. We describe an unusual case of a minor salivary gland papillary mucinous neoplasm presenting in a novel location (subglottic larynx) with a novel mutational driver for this entity (GNAS R844H mutation), and briefly review the literature surrounding SG IPMN, its classification and related tumours.

These findings yield valuable insights into the biological and clinical behaviors of this rare parotid gland neoplasm. Furthermore, this work enhances the understanding of the epidemiological characteristics and optimal management strategies for parotid gland SCNC.

This case suggests that a subset of adnexal adenocarcinomas of not otherwise specified type (NOS) may carry PRKD alteration and may constitute the cutaneous counterpart of salivary gland PAC/CASG. This finding argues in favor of a more systematic molecular exploration of adnexal adenocarcinomas NOS for better classification and prognosis.